Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Oncodesign Signs a Partnership Agreement with Sanofi

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Oncodesign will apply its Nanocyclix® technology to one of Sanofi's kinase targets.

Oncodesign has announced that it has signed a second research collaboration agreement with Sanofi.

This partnership follows a first agreement signed in summer 2012, relating to a number of kinase targets being developed by Sanofi. This second agreement aims to identify inhibitors of a kinase which plays a key role in tissue protection and repair.

Oncodesign will use its Nanocyclix® technology to design and synthesize potent new selective inhibitors. Sanofi will have exclusive licensing rights to the molecules that result from the collaboration.

Nanocyclix is a proprietary medicinal chemistry technology and a research platform based on a chemical macrocyclization process.

The kinase inhibitors obtained using this process are potent and highly selective, because their structures demonstrate exceptional shape complementarity with the binding site of the kinase ATP (adenosine triphosphate).

The resulting selectivity is unparalleled, especially for kinases that are highly homologous. Drawing on proven expertise, the technology also allows the pharmacokinetic properties of Nanocyclix compounds to be enhanced at an increased rate.

Oncodesign leads the field in macrocyclic kinase inhibitors, offering partnership opportunities based on its own research programs and partners' programs that target the kinases to which the Nanocyclix technology is applied.

“This new agreement with Sanofi demonstrates the level of interest in our Nanocyclix technology from some of the most well-renowned pharma companies. This is our third collaboration agreement in a year of drug discovery, establishing our company as a leader in the field of kinase inhibitors in a variety of therapeutic areas,” says Dr Philippe Genne, chairman, CEO and founder of Oncodesign.

Under the terms of the agreement, Oncodesign will apply its Nanocyclix technology to a key target implicated in the therapeutic area of tissue protection and repair.

The cost of the initial phase of the work is to be met in full by Sanofi, who will have exclusive rights to the results of the program. The financial details have not been disclosed.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncodesign Enters into a Services Agreement with Eisai
The program aims to identify useful patient stratification biomarkers for Eisai’s Halaven® eribulin using patient-derived xenograft models.
Friday, December 26, 2014
Oncodesign and UCB Enter into a Research Collaboration
The partnership is based on Oncodesign's Nanocyclix® technology platform for next generation kinase inhibitors and UCB’s expertise in neurology.
Thursday, November 14, 2013
Oncodesign Signs Partnership Agreement with Sanofi
Oncodesign will apply its Nanocyclix(R) technology to one of Sanofi's kinase targets.
Thursday, March 28, 2013
Oncodesign Enters into a Research Collaboration and License Agreement with Sanofi
Collaboration for the application of Oncodesign’s Nanocyclix® technology to Sanofi’s kinase targets.
Saturday, September 15, 2012
Oncodesign and Ipsen Enter into a Research Collaboration
Partnership is based on Oncodesign's Nanocyclix(R) Technology for next generation kinase inhibitors and Ipsen’s expertise in Movement Disorders.
Thursday, January 05, 2012
Oncodesign and Ipsen Enter Into a Research Collaboration
Partnership is based on Oncodesign's Nanocyclix® technology for next generation kinase inhibitors and Ipsen’s expertise in movement disorders.
Thursday, January 05, 2012
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos